Illumina, Inc. (ILMN)

433,20 -1,39 (-0,32 %) À la clôture : 4:00PM EDT

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
United States
858 202 4500
http://www.illumina.com

Secteur(s): Healthcare
Secteur d’activité: Diagnostics & Research
Employés à temps plein: 7 800

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Francis A. deSouza	CEO & Director	S.O.	S.O.	1971
Mr. Sam A. Samad	Chief Financial Officer	716,04k	S.O.	1970
Dr. Alexander Aravanis M.D., Ph.D.	CTO & Head of Research and Product Devel.	416,48k	S.O.	1976
Ms. Susan H. Tousi	Chief Commercial Officer	655,31k	S.O.	1969
Stephanie Campos	Pres	S.O.	S.O.	S.O.
Mr. Robert P. Ragusa	Chief Operations Officer	S.O.	S.O.	1960
Mr. Jose A. Torres Jr.	Chief Accounting Officer & VP	S.O.	S.O.	1975
Mr. Steve Phillpott	Sr. VP & Chief Information Officer	S.O.	S.O.	S.O.
Mr. Charles E. Dadswell	Sr. VP, Gen. Counsel & Sec.	S.O.	S.O.	1959
Mr. Eric Endicott	Sr. Director of Corp. Communications	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2020 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has collaboration agreements with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer; LetsGetChecked to track COVID-19 variants in California; and Merck & Co., Inc. to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. The company was incorporated in 1998 and is headquartered in San Diego, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Illumina, Inc. en date du 1 juillet 2021 est 6. Les scores principaux sont Audit : 3; Société : 1; Droits des actionnaires : 6; Compensation : 9.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.